drugset / Trial / NCT06202612

A SHR0302 BA Study on Healthy Subjects

NCT06202612

Phase 1 Completed 16 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate and compare the pharmacokinetics of SHR0302 two different kind tablets in Healthy subjects after administration two kind tablets (quick release tablets and sustained-release tablets).

Timeline

Start
2024-01-16
Primary completion
2024-02-21
Completion
2024-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR0302 Unknown 8 mg
Subject SHR0302 Unknown 10 mg

Indications